Менопаузальная гормональная терапия: новый взгляд на старые проблемы
https://doi.org/10.21518/2079-701X-2019-13-138-141
Abstract
The most effective symptomatic treatment of menopause is menopausal hormone therapy (MHT). It has been shown that MHT administered in proper time can not only reduce the frequency and intensity of vasomotor disorders, but also significantly reduce the risk of osteoporosis and coronary heart disease (CHD). However, several research showed the increased risk of venous thromboembolism, stroke and breast cancer in patients receiving MHT, thereby MHT safety was questioned. Despite the fact that the beneficial properties of MHT significantly exceed the possible risks of side effects, modern international guidelines recommend to use minimal doses of MHT. Low-dose and ultra-low dose MHT regimens make it possible to maintain effectiveness, but at the same time reduce the incidence of undesirable side reactions to a minimum.
About the Author
Yu. S. Drapkina
Federal State Budgetary Institution «National Medical Research Center of Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Drapkina Yulia Sergeevna, Obstetrician-Gynecologist, Postgraduate Student
117997, Russia, Moscow, 4, Oparina str.
References
1. Harlow S.D., Gass M., Hall J.E., et al. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Climacteric. 2012;15(2):105–114.
2. Hoffman B. Williams Gynecology. New York: McGraw-Hill Medical. 2012:555–56.
3. ESHRE Capri Workshop Group. Perimenopausal risk factors and future health. Human Reproduction Update. 2011;17(5):706–17.
4. Boardman H.M., Hartley L., Eisinga A., Main C., Roque i Figuls M., Bonfill Cosp X., Gabriel Sanchez R, Knight B. Hormone therapy for preventing cardiovascular disease in post-menopausal women. The Cochrane Database of Systematic Reviews. 2015 Mar 10(3).
5. North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010;(17):242–255.
6. Regidor P.A. Progesterone in Periand Postmenopause: A Review. Geburtshilfe Frauenheilkd. 2014;74(11):995–1002.
7. Smetnik А.А. Menopausal hormone therapy with dydrogesterone: aspects of efficacy and safety of ultra-low doses. Medicinskij sovet = Medical Council. 2017;(2):92-99. (In Russ.) doi: 10.21518/2079-701X-2017-2-92-99.
8. Stevenson J.C., Durand G., Kahler E. et al. Oral ultralow dose continuous combined hormone replacement therapy with 0.5 mg 17betaoestradiol and 2.5 mgdydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study. Maturitas, 2010;(67):227–32.
9. Maki P.M., Drogos L.L., Rubin L.H., Banuvar S., Shulman L.P., Geller S.E. Objective hot flashes are negatively related to verbal memory performance in midlife women. Menopause. 2008 Sep-Oct;15(5):848-56.
10. Gambacciani M., Cappagli B., Ciaponi M., Pepe A., Vacca F., Genazzani A.R. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Maturitas. 2008;(59):2–6.
11. Stevenson J.C., Panay N., Pexman-Fieth C. Oral estradiol and dydrogesterone combination therapy in postmenopausal women: Review of efficacy and safety. Maturitas. 2013;(760:10-21.
12. Schierbeck L.L., Rejnmark L., Tofteng C.L. et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. British Medical Journal. 2012;(345):e6409.
13. Anderson G.L., Chlebowski R.T., Aragaki A.K., et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended followup of the Women’s Health Initiative randomisedplacebocontrolled trial. The Lancet Oncology. 2012;(13):476–86.
14. Khalid Rida Murshid. A Review of Mastalgia in Patients with Fibrocystic Breast Changes and the Non-Surgical Treatment Options. Journal of Taibah University Medical Sciences. 2011;6(Issue 1):1-18.
15. Fournier A., Berrino F., Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;(107):103–111.
16. Schneider C., Jick S.S., Meier C.R. Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations. Climacetric. 2009:1–11 ([Epub ahead of print]).
17. Bergeron C., Nogales F.F., Rechberger T. et al. Ultra low dose continuous combined hormone replacement therapy with 0.5 mg 17beta-oestradiol and 2,5 mg dydrogesterone: protection of the endometrium and amenorrhoea rate. Maturitas. 2010;66(2):201-205.
Review
For citations:
Drapkina YS. . Meditsinskiy sovet = Medical Council. 2019;(13):138-141. (In Russ.) https://doi.org/10.21518/2079-701X-2019-13-138-141
Views:
728
Email this article 